12 results about "Tumor necrosis factor alpha" patented technology

The invention provides an application of a compound as shown in a formula I, cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury, and application of the compound in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury in preparation of drugs for prevention, alleviation, adjuvant therapy or treatment of lung injury. The compound shown in the formula I can obviously reduce proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) of an acute lung injury rat model, improve infiltration of inflammatory cells (including mononuclear / macrophage, lymphocyte and neutrophil) in lung tissues, improve pathological injury of the lung tissues, improve lung functions, and improve the curative effect of the lung. The above results show that the compound represented by the formula I can be used for prevention, alleviation, adjuvant therapy or treatment of lung injury, especially acute lung injury or a combined disease thereof or acute respiratory distress syndrome or a combined disease thereof.

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.

The present invention discloses an exosome-based delivery vehicle for targeted delivery of an active substance to cancer cells and cancer stem cells. The delivery vehicle is obtained by a method including the steps of incubating monocytes in a culture medium containing a biologic to obtain dendritic cells, adding an active substance to the culture medium containing the dendritic cells to obtain an exosome-based delivery vehicle containing the active substance, and isolating the exosome-based delivery vehicle from the culture medium for targeted delivery of the active substance specific to cancer cells and cancer stem cells. The present invention also discloses a biologic for enhancing the specificity of the exosome-based delivery vehicle to cancer cells and cancer stem cells. The biologic includes granulocyte macrophage colony stimulating factor, interleukin-4, ionomycin, tumor necrosis factor alpha, IL1β, LPS, and angiotensin II.

A treatment for psoriasis is provided herein, wherein a human subject is administered a daily dose of 400 mg of compound 1 or a pharmaceutically acceptable salt thereof.

The present invention relates to antibody molecules and functional fragments thereof, capable of binding to tumor necrosis factor alpha (TNFα), to processes for their production, and to their therapeutic uses.

The invention provides a biomarker combination for detecting brain functional diseases. The biomarker combination comprises four protein markers, namely a glial fibrillary acidic protein (GFAP), an interleukin-6 (IL-6), an interleukin-1beta (IL-1beta) and a tumor necrosis factor alpha (TNF-alpha). The combined detection sensitivity of GFAP, IL-6, IL-1beta and TNF-alpha in a training column set can reach 85.26%, the specificity can reach 88.04%, and the area (AUC) under an ROC curve can reach 0.866. When the blood protein marker combination is used for preparing a reagent for detecting and evaluating the brain function of a patient, the disease diagnosis sensitivity can be improved, and the blood protein marker combination has the advantages of high specificity, good stability, rapid detection and the like. The biomarker combination disclosed by the invention can be applied to products for disease risk prediction, screening, prognosis evaluation, treatment effect monitoring or relapse monitoring and the like of brain function related diseases.

The present invention relates to the use of Desulfovibrio species, optionally contained in fecal matter, for the prevention or treatment of inflammation-related diseases, including type 1 diabetes mellitus, autoimmune diseases, inflammatory diseases, and cardiovascular diseases. The Desulfovibrio species may be selected from Desulfovibrio piger, Desulfovibrio fairfieldensis, Desulfovibrio desulfuricans, and related species, with specific administration methods such as enteral, oral, nasal, or rectal routes. The bacteria may be formulated in pharmaceutical compositions, including capsules, tablets, or powders, optionally encapsulated with an enteric coating. Additionally, Desulfovibrio species may be combined with tumor necrosis factor alpha (TNFα) inhibitors or probiotic bacteria such as Bifidobacteria and Lactobacillales to enhance therapeutic effects. The composition may contain live or attenuated bacterial cells in specific concentrations. The invention provides novel approaches for modulating gut microbiota to address inflammation-related disorders in mammals, particularly humans.

A method for selecting a patient for anti-CLEVER-1 therapy prior to initiating anti-CLEVER-1 therapy using one or several of the inflammatory markers selected from interferon gamma (IFNγ), tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 8 (IL-8), and C-reactive protein. If the measured level of the inflammatory marker is substantially within the reference value of the inflammatory marker or lower than the average reference value of the inflammatory marker, it is an indication for selecting the patient and initiating anti-CLEVER-1 therapy.

The invention discloses a verbena extract with an anti-radiation effect and a preparation method and application thereof.The preparation method comprises the specific steps that the overground part of verbena is taken, ethyl alcohol is added for heating reflux operation, and then the obtained mixed solution is filtered to obtain an extracting solution; the extraction process is repeated for 1-3 times, then extracting solutions obtained in multiple times are combined, concentration and drying treatment are carried out, and finally an extractum-like substance, namely the verbena extract, is obtained. The traditional Chinese medicine composition can effectively improve the morphology and pathological change of spleen tissues, significantly increase the counting level of peripheral blood leukocytes (WBC), neutrophils (NE) and lymphocytes (LY), and reduce the release of inflammatory factors such as tumor necrosis factor alpha (TNF-alpha), interleukin 17 (IL-17) and interleukin 6 (IL-6); in this way, the tissue damage degree caused by radiation can be practically reduced, and a potential effective intervention means is provided for treating radiation damage.

Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.

Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.

The present disclosure relates to methods, compositions, and kits for treating traumatic brain injury (TBI) and TBI-associated impairments in a subject. The methods include administering to the subject an interleukin-7 (IL-7) or IL-7 agonist, a tumor necrosis factor alpha (TNFα) inhibitor, or both. The present disclosure also relates to methods of using biomarkers for identifying a subject that is likely to respond to a treatment for TBI-associated impairments, and monitoring the subject's response to such treatment.